Alpha4 Integrin Antagonists Block HIV Gp120 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HIV infection, such as highly active antiretroviral therapy (HAART), have toxicities and existing agents like monomeric soluble CD4 (sCD4) fail to efficiently neutralize primary HIV isolates, highlighting a need for alternative therapies that can target HIV replication and infection effectively.
Innovation Solution
Administering α4 integrin antagonists, including antibodies, peptides, or small molecules, that interfere with the interaction between HIV envelope protein gp120 and α4 integrin on CD4+ T-cells, natural killer cells, and CD8+ T-cells to reduce HIV infectivity and replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HAART is used to treat HIV infection, then viral load is reduced, but toxicities occur
Solution Approach 1:
The patent extracts the CD4 binding site from the complex HAART regimen and targets it specifically with gp120-binding agents. This selective targeting approach eliminates the need for multiple toxic drugs while achieving viral load reduction through a single mechanism of action that blocks HIV entry without the broad-spectrum toxicities of HAART.
Solution Approach 2:
The patent uses gp120-binding agents as intermediary substances that mediate between the virus and host cells. These agents bind to the CD4 binding site on gp120, preventing viral entry without directly attacking the virus or requiring multiple concurrent drugs, thus reducing toxicity while maintaining effectiveness.
2Device complexity
If sCD4 is used to block gp120-CD4 interaction, then CD4 binding is inhibited, but antiviral activity is insufficient
Solution Approach 1:
The patent changes the binding parameters by using agents with higher affinity for the CD4 binding site compared to sCD4. These agents bind more tightly to gp120, preventing viral entry more effectively. The patent also explores different binding mechanisms and affinities to optimize antiviral activity while maintaining the simple blocking mechanism.
3Reliability
If CD4 binding site agents are used, then de novo infection is blocked, but resistance mutants may arise
Solution Approach 1:
The patent applies partial action by targeting only the CD4 binding site rather than multiple viral proteins simultaneously. This selective approach blocks de novo infection effectively. The patent also explores using agents that bind to conserved regions of gp120, which are less likely to mutate, thereby reducing the risk of resistance while maintaining infection blocking capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of α4 integrin antagonists effectively reduces HIV infection efficiency and replication by blocking gp120 binding to α4 integrin, potentially delaying disease progression and reducing viral load without the toxicities associated with HAART.
Implementation Method 1
the HIV-1 envelope protein gp120 binds to α4β7 integrin on CD4+ T-cells, natural killer (NK) cells and CD8+ T-cells. For example, interference with gp120 binding to α4β7 integrin reduces the efficiency of infection of suboptimally activated CD4+ T-cells
Data Source
AI summary
Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist, thereby treating the HIV infection. In several examples, the α4 integrin antagonist is a monoclonal antibody that specifically binds to a α4, β1 or β7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.